{"name":"Immatics Biotechnologies GmbH","slug":"immatics-biotechnologies-gmbh","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"APVAC1 vaccine plus Poly-ICLC and GM-CSF","genericName":"APVAC1 vaccine plus Poly-ICLC and GM-CSF","slug":"apvac1-vaccine-plus-poly-iclc-and-gm-csf","indication":"Non-small cell lung cancer","status":"phase_1"},{"name":"APVAC2 vaccine plus Poly-ICLC and GM-CSF","genericName":"APVAC2 vaccine plus Poly-ICLC and GM-CSF","slug":"apvac2-vaccine-plus-poly-iclc-and-gm-csf","indication":"Non-small cell lung cancer","status":"phase_1"},{"name":"IMA901","genericName":"IMA901","slug":"ima901","indication":"Metastatic renal cell carcinoma (in combination with sunitinib)","status":"phase_3"}]}],"pipeline":[{"name":"APVAC1 vaccine plus Poly-ICLC and GM-CSF","genericName":"APVAC1 vaccine plus Poly-ICLC and GM-CSF","slug":"apvac1-vaccine-plus-poly-iclc-and-gm-csf","phase":"phase_1","mechanism":"APVAC1 vaccine targets tumor antigens, Poly-ICLC is a Toll-like receptor 3 agonist, and GM-CSF is a granulocyte-macrophage colony-stimulating factor.","indications":["Non-small cell lung cancer","Melanoma"],"catalyst":""},{"name":"APVAC2 vaccine plus Poly-ICLC and GM-CSF","genericName":"APVAC2 vaccine plus Poly-ICLC and GM-CSF","slug":"apvac2-vaccine-plus-poly-iclc-and-gm-csf","phase":"phase_1","mechanism":"APVAC2 vaccine plus Poly-ICLC and GM-CSF is a cancer immunotherapy that targets tumor cells by stimulating the immune system through activation of dendritic cells and subsequent activation of T cells.","indications":["Non-small cell lung cancer"],"catalyst":""},{"name":"IMA901","genericName":"IMA901","slug":"ima901","phase":"phase_3","mechanism":"IMA901 is a personalized neoantigen vaccine that trains the immune system to recognize and attack cancer cells expressing patient-specific tumor mutations.","indications":["Metastatic renal cell carcinoma (in combination with sunitinib)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5MNFhIY0I3aVBsT0U5MUpydG85SUI2MnFKc0FpRXV2SjQ1VktoY09Ec2NUMERUMW1aTjA1M3BBUmNBRnNST1J4eXRvbHZDb3ZnOFNEY3JTWXRjZGpkelVj?oc=5","date":"2025-04-09","type":"trial","source":"nature.com","summary":"Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial | Nature Medicine - nature.com","headline":"Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial | Nature Medicine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNMEpjdXpQczBMTnpRelNDQ0VNVmlrd25leldnUTVTRzJWZXFUQnFBZkJWTHBkVmFjeDZVa1dPYm1WcGJPczVBRFZCQjc2anprYjJEX2xHckxWZjlnRlJITVBtVVljTnNCVjhWZTg1ZWI5RFpOSXJOUmR3ZGVpQWRQRFlzUThJcUdlRGhFRkxucVUzUmZBbFE?oc=5","date":"2024-12-20","type":"patent","source":"drugdiscoverytrends.com","summary":"25 leaders in cell and gene therapy patents from 2020 to 2024 - drugdiscoverytrends.com","headline":"25 leaders in cell and gene therapy patents from 2020 to 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPOVJSbUUzVEw5UG1KOEo1aVczTUYwTFhuOFNWUXFKTEVncTlreTB0M3A3Ukk2MzBoQ2FXeFJvRkQ2dmxqZWdYd0M2NlhxNUVwSmtTQmlhYkt4cXlFVkRJV0sxcHRHWC1FaUJ5VGFpMV9rRjJyMmVwTXh5Ny1CZzJ0NHhoR0tKRjdacnNqREZZeVlWcFk?oc=5","date":"2024-01-18","type":"pipeline","source":"Pharmaceutical Technology","summary":"Immatics to raise $175m in public offering - Pharmaceutical Technology","headline":"Immatics to raise $175m in public offering","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQRHgyTXdRM2J4VlE2eGExeEQtbFB3ZVZpbmhuNTByNUh5cEFvbkVHb1ozZDRTNFphdEZaM2J2S0Q4Vy1ySWlSQW82UzYtYUN0bDdzdjRZOWQ3UUVHeDU3aU9MMWt1VjRXeXg3S0xlZVEwcXlqRUNRcFhONThNNk9xcw?oc=5","date":"2021-09-07","type":"pipeline","source":"Fierce Biotech","summary":"SPAC Attack: The 10 biggest in biotech - Fierce Biotech","headline":"SPAC Attack: The 10 biggest in biotech","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_1":2,"phase_3":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}